NCT00103168

Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor

Intermediate and High Risk Localized, Completely Resected, Gastrointestinal Stromal Tumors (GIST) Expressing KIT Receptor: A Controlled Randomized Trial on Adjuvant Imatinib Mesylate (Glivec) Versus No Further Therapy After Complete Surgery

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 908 (actual)
• Sponsor: European Organisation for Research and Treatment of Cancer - EORTC · Network
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving imatinib mesylate after surgery may kill any remaining tumor cells. It is not yet known whether imatinib mesylate is more effective than observation only in treating gastrointestinal stromal tumor. PURPOSE: This randomized phase III trial is studying imatinib mesylate to see how well it works compared to observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor.

Detailed description

OBJECTIVES: Primary * Assess whether there is a difference in overall survival between intermediate and high-risk localized GIST patients undergoing complete surgery alone and those undergoing complete surgery plus adjuvant imatinib mesylate 400 mg daily for two years Secondary * Assess whether there is a difference in relapse-free survival and relapse-free interval between GIST undergoing complete surgery alone and those undergoing surgery + adjuvant Imatinib mesylate 400 mg daily for two years. * Determine the safety of this drug in these patients. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to participating center, risk category (high vs intermediate), tumor site (gastric vs other), and resection level (R0 vs R1). * Arm I: Patients receive adjuvant oral imatinib mesylate once daily for 2 years in the absence of disease progression or unacceptable toxicity. * Arm II: Patients are observed (without receiving further antitumoral therapy) every 3 months for 2 years. After completion of study treatment, patients in arm I are followed every 3 months for 2 years. All patients are then followed every 4 months for 3 years and at least annually thereafter. PROJECTED ACCRUAL: A total of 900 patients will be accrued for this study within 3.5 years.

Conditions

• Gastrointestinal Stromal Tumor

Interventions

Type	Name	Description
DRUG	imatinib mesylate	400 mg/day for 2 years

Timeline

• Start date: 2004-12-01
• Primary completion: 2008-10-01
• Completion: 2017-09-01
• First posted: 2005-02-08
• Last updated: 2018-07-09

Locations

50 sites across 6 countries: Australia, Denmark, France, Germany, Spain, United Kingdom